Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2025 07:05 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics inleder doseringen i en klinisk fas 2a-studie i patienter med kronisk njursjukdom med anemi

STOCKHOLM, 10 december, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har doserat den första patienten i den kliniska fas 2a-studien som...
December 10, 2025 07:05 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia

STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a...
December 10, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag AnaCardio presenterar positiva top line-resultat från fas 2a-studien med läkemedelskandidaten AC01

STOCKHOLM, 10 december 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio presenterat starka och positiva top line-resultat från den kliniska fas...
December 10, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01

STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has reported strong, positive results from the phase 2a...
December 02, 2025 04:24 ET | Source: Karolinska Development AB (publ)

Aktieägarna i Karolinska Development AB (publ) kallas till extra bolagsstämma

Aktieägarna i Karolinska Development AB (publ), org.nr 556707-5048, (“Karolinska Development” eller “Bolaget”), kallas till extra bolagsstämma torsdagen den 8 januari 2026 kl. 10.00 hos Cirio...
December 02, 2025 04:24 ET | Source: Karolinska Development AB (publ)

Notice of Extraordinary General Meeting in Karolinska Development AB (publ)

The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting (“EGM”), on Thursday January 8,...
December 01, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development AB (publ) offentliggör företrädesemission om upp till cirka 203 MSEK, villkorat av bolagsstämmans efterföljande godkännande samt föreslår namnbyte till KDventures AB

EJ AVSEDD FÖR DISTRIBUTION ELLER PUBLICERING, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, KANADA, JAPAN, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDKOREA, SYDAFRIKA ELLER INOM...
December 01, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
November 17, 2025 03:16 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition publicerar data om fördelar av tidig behandling med golexanolon vid Parkinsons sjukdom

STOCKHOLM, 17 november 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterat data som visar varaktiga fördelar av tidig behandling med...
November 17, 2025 03:16 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition publishes data on the benefits of early treatment with golexanolone in Parkinson’s disease

STOCKHOLM – November 17, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has published data in the scientific journal...